Allowance by the USPTO on a Novel Antibody Mimics Library
Welcome to Protelica
Pronectins™ are newly designed “antibody mimics”, based on our proprietary Human Loop
Database, Diversity-generating Mutagenesis, Look-Through and Walk-Through Mutagenesis, and
a novel human fibronectin scaffold (14Fn3), meant to replace the first generation MAb for a
variety of human diseases. Protelica has developed a pipeline of highly specific Pronectins™ that
are being tested at the pre-clinical stage for cancer immunotherapy and other diseases where
MAb treatment has shown limited efficacy. Pronectins’ size (1/15 of the MAb MW), stability,
specificity, lack of immunogenicity and cost of manufacturing make these proprietary
single-domain proteins a very promising novel class of protein therapeutics, whether used by
themselves or in combination with other protein structures.
Protelica was founded by Dr. Roberto Crea, who has developed innovative protein engineering
technologies since his first instrumental involvement with Genentech in 1977 as the first Director
of DNA Chemistry and through his 35+ years of entrepreneurial career in
Partnering Opportunities
Protelica is focused initially on developing oncology products where there is a significant benefit for patients, including targeted therapies for
cancer types that are deemed intractable by currently available small molecule and monoclonal antibody therapies. Protelica is interested in
establishing a portfolio of strategic collaborations with key partners and is open to discuss areas of potential common interest in the oncology
space from which to build value for both parties.
Innovation
Intelligent Mutagenesis
Protelica has developed a number of patented DNA
mutagenesis technologies for protein affinity maturation:
Walk-Through Mutagenesis™ (WTM), Look-Through
Mutagenesis™ (LTM) and Combinatorial Beneficial Mutation
™ (CBM). The processes use a rational, chemistry-based […]
Read More
Pronectin™ Technology
Protelica has developed a number of patented DNA
mutagenesis technologies for protein affinity maturation:
Walk-Through Mutagenesis™ (WTM), Look-Through
Mutagenesis™ (LTM) and Combinatorial Beneficial Mutation
™ (CBM). The processes use a rational, chemistry-based […]
Read More
Patents
Protelica has developed a number of patented DNA
mutagenesis technologies for protein affinity maturation:
Walk-Through Mutagenesis™ (WTM), Look-Through
Mutagenesis™ (LTM) and Combinatorial Beneficial Mutation
™ (CBM). The processes use a rational, chemistry-based […]
Read More
Therapeutics
Oncology Applications
Our innovative approach focuses on the development
of a diverse array of next-generation protein
therapeutics including Pronectin™ cancer
immunotherapies, Pronectin™ drug conjugates
(PDCs), T-cell engaging Pronectin™ and bi-specific […]
Read More
ProCAR-T™
Chimeric-antigen receptor (CAR)-T cell
immunotherapy is a promising type of cancer therapy
which consists of a target binding domain of an
antibody that is specific to the target antigen on the
cancer cell surface. This domain extends out […]
Read More
Bi-Specific Pronectins™
A bispecific antibody is a single therapeutic molecule
designed to bind two different targets. Bispecific
antibodies have the advantage of combining two
therapeutic mechanisms with the goal of increasing
therapeutic efficacy, in comparison […]
Read More
Other Applications
Protelica is applying its extensive protein discovery,
development, and pre-clinical experience to develop
our pipeline of Pronectin™ therapeutic products, with
the initial focus on oncology. Beyond cancer,
development of highly differentiated Pronectin™ […]
